Incyte Corp. has synthesized diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
The University of Florida has prepared and tested PPARγ agonists reported to be useful for the treatment of diabetes, hyperparathyroidism, metabolic syndrome, multiple myeloma, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), obesity, osteoporosis and Paget disease, among others.
Angel Pharmaceuticals Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Johns Hopkins University has discovered daunorubicin derivatives reported to be useful for the treatment of cancer, including glioblastoma, diffuse midline glioma and diffuse intrinsic pontine glioma.
Beijing Neox Biotech Co. Ltd. has patented proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to wee1-like protein kinase (Wee1) binding moiety through a linker reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to RACα serine/threonine-protein kinase AKT targeting moiety through a linker reported to be useful for the treatment of prostate cancer.
Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have described cyclin-dependent kinase 12 (CDK12) inhibitors reported to be useful for the treatment of cancer.
Thirtyfivebio Ltd. has divulged G-protein coupled receptor GPR35 antagonists reported to be useful for the treatment of cancer, inflammation, fibrosis, cardiovascular, gastrointestinal and immunological disorders.
TYK Medicines Inc. has patented compounds reported to be useful for the treatment of Alzheimer’s, Parkinson’s and Huntington diseases as well as amyotrophic lateral sclerosis, epilepsy and spinocerebellar ataxia.
RSS